RXRX is trading 5% up at $3.85 as the stock continues to build on a series of incremental gains over the past week, moving higher despite slight weakness in the major indices.
- The move appears to be a continuation of recent momentum and positive sentiment surrounding the company's AI-driven drug discovery story rather than a reaction to a specific headline.
- There are no fresh earnings, FDA developments, M&A news, or major analyst actions dated July 01, 2026, specifically tied to the company.
- The stock's relative strength comes as it outperforms the broader market trend during today's session.